Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PSTV

Plus Therapeutics Inc

Sep 20 • 03:21PM ET

1.52

Dollar change -0.08
Percentage change -4.94	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.87	Insider Own	2.48%	Shs Outstand	5.90M	Perf Week	2.77%
Market Cap	8.97M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	151.62%	Shs Float	5.75M	Perf Month	4.18%
Income	-13.23M	PEG	-	EPS next Q	-0.56	Inst Own	11.56%	Short Float	0.61%	Perf Quarter	-15.50%
Sales	5.51M	P/S	1.63	EPS this Y	47.46%	Inst Trans	-4.77%	Short Ratio	0.64	Perf Half Y	-16.43%
Book/sh	-1.34	P/B	-	EPS next Y	7.63%	ROA	-104.14%	Short Interest	0.03M	Perf Year	20.71%
Cash/sh	1.43	P/C	1.06	EPS next 5Y	-	ROE	-522.50%	52W Range	0.97 - 2.78	Perf YTD	-13.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	68.20%	ROI	-	52W High	-45.29%	Beta	0.67
Dividend TTM	-	Quick Ratio	0.50	Sales past 5Y	406.45%	Gross Margin	86.24%	52W Low	56.90%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	0.50	EPS Y/Y TTM	62.10%	Oper. Margin	-256.07%	RSI (14)	51.73	Volatility	8.24% 8.28%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	113.20%	Profit Margin	-240.15%	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	53.66%	Payout	-	Rel Volume	0.17	Prev Close	1.60
Sales Surprise	-24.76%	EPS Surprise	15.09%	Sales Q/Q	-31.01%	Earnings	Aug 14 AMC	Avg Volume	54.82K	Price	1.52
SMA20	5.42%	SMA50	-3.49%	SMA200	-17.51%	Trades		Volume	8,530	Change	-4.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Sep-18-24 07:30AM	Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire)
Sep-04-24 07:30AM	Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-15-24 09:42AM	Q2 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 09:53PM	PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
04:16PM	Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:30AM	Loading…
Aug-13-24 07:30AM	Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire) +5.67%
Aug-12-24 07:30AM	Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Aug-08-24 07:30AM	Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference (GlobeNewswire)
Jul-02-24 07:30AM	Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer (GlobeNewswire)
Jun-07-24 07:30AM	Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT (GlobeNewswire) -5.24%
May-17-24 05:00PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-16-24 03:05AM	Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com)
May-15-24 08:53PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.91%
04:15PM	Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:30AM	Loading…
May-13-24 07:30AM	Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 (GlobeNewswire)
May-09-24 11:29AM	Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial (GlobeNewswire)
May-08-24 05:35PM	Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial (GlobeNewswire) +6.57%
May-06-24 07:30AM	Plus Therapeutics Announces Private Placement Financing of up to $18 Million (GlobeNewswire) +11.67%
Apr-22-24 09:00AM	Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense (Benzinga)
07:00AM	Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense (GlobeNewswire)
Apr-09-24 07:00AM	Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team (GlobeNewswire)
Mar-27-24 08:00AM	Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference (GlobeNewswire)
Mar-25-24 08:00AM	Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic (GlobeNewswire)
Mar-11-24 07:00AM	Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire)
Mar-07-24 08:59AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Mar-06-24 01:43PM	Q4 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Loading…
Feb-27-24 08:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024 (GlobeNewswire) +6.01%
Dec-18-23 07:00AM	Plus Updates Financial and Cash Guidance for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses (GlobeNewswire)
Nov-29-23 08:00AM	Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire) -5.56%
Nov-20-23 07:00AM	Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -27.76%
Nov-15-23 07:00AM	Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023 (GlobeNewswire) +12.43%
Nov-13-23 09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
Nov-03-23 07:00AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases (GlobeNewswire) +17.65%
Nov-01-23 09:29AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.74%
Oct-31-23 04:10PM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire) +10.92%
04:05PM	Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-25-23 09:21AM	Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -7.34%
Oct-23-23 04:05PM	Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023 (GlobeNewswire) -5.22%
Oct-10-23 07:00AM	Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire) +5.04%
Oct-09-23 07:00AM	Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October (GlobeNewswire)
Sep-19-23 01:07PM	Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE (Exec Edge)
Sep-15-23 11:17AM	Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc (GuruFocus.com)
Sep-11-23 12:44PM	Plus Therapeutics Presents Cancer Treatment Data at Conference (Exec Edge) +8.70%
07:00AM	Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference (GlobeNewswire)
Sep-08-23 12:49PM	Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform (Exec Edge) -53.54%
11:18AM	Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today? (Benzinga)
08:30AM	EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers (Benzinga)
07:00AM	Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay (GlobeNewswire)
Sep-05-23 01:13PM	Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid (Exec Edge)
07:00AM	Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase (GlobeNewswire)
Aug-30-23 07:00AM	Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 09:55AM	Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:58AM	Q2 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:05PM	Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-11-23 06:28PM	Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics (Exec Edge) -20.89%
08:00AM	EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer (Benzinga)
06:30AM	Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-08-23 04:05PM	Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023 (GlobeNewswire) +10.14%
11:22AM	Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-03-23 07:00AM	Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-27-23 05:34PM	Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations (Exec Edge) -9.02% +5.17%
04:05PM	Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations (GlobeNewswire)
07:00AM	Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Jul-13-23 07:00AM	Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit (GlobeNewswire)
Jun-29-23 07:00AM	Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) -5.38%
Jun-14-23 07:00AM	Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -10.68%
Jun-08-23 07:00AM	Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting (GlobeNewswire)
Jun-01-23 07:00AM	Plus Therapeutics Provides Company Update Today (GlobeNewswire)
May-30-23 07:00AM	Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023 (GlobeNewswire) -7.19%
May-25-23 07:00AM	Plus Therapeutics to Present at the 2023 Virtual June Investor Summit (GlobeNewswire)
May-16-23 07:00AM	Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -7.09%
May-12-23 07:00AM	Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event (GlobeNewswire) -8.47%
May-02-23 07:00AM	Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials (GlobeNewswire) -7.27%
Apr-28-23 12:55PM	Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-21-23 09:01AM	Q1 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.98%
Apr-20-23 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.83%
04:05PM	Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Apr-18-23 04:15PM	Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire)
07:00AM	Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (GlobeNewswire)
Apr-12-23 07:00AM	Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023 (GlobeNewswire)
Mar-28-23 07:00AM	Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Mar-22-23 07:00AM	Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases (GlobeNewswire)
Feb-23-23 05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.89%
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Feb-14-23 07:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (GlobeNewswire)
Feb-01-23 07:00AM	Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹Re) Obisbemeda for the Treatment of Leptomeningeal Metastases (GlobeNewswire) -8.29%
Jan-18-23 07:00AM	Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Jan-05-23 04:15PM	Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision (IPO-Edge.com) +15.96%
Nov-21-22 06:53AM	Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications (Benzinga)
Nov-19-22 08:24AM	Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire)
Nov-02-22 07:00AM	Plus Therapeutics to Provide Update on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) -6.38%
Oct-26-22 07:00AM	Plus Therapeutics Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL (GlobeNewswire)
Oct-20-22 04:05PM	Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-19-22 07:00AM	Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress (GlobeNewswire)

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawkins Richard J	Director	Sep 13 '24	Buy	1.50	4,000	5,996	15,188	Sep 17 07:00 AM
Hawkins Richard J	Director	Sep 12 '24	Buy	1.35	6,285	8,512	11,188	Sep 16 07:00 AM
Petersen Greg	Director	Sep 11 '24	Buy	1.35	12,500	16,875	48,921	Sep 13 06:04 AM
Clowes Howard	Director	Sep 11 '24	Buy	1.34	5,000	6,681	26,497	Sep 13 06:04 AM
HEDRICK MARC H	Chief Executive Officer	Sep 10 '24	Buy	1.23	8,000	9,839	20,425	Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Sep 10 '24	Buy	1.27	4,098	5,204	9,815	Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	May 08 '24	Buy	2.04	4,902	10,000	5,717	May 10 07:30 AM
HEDRICK MARC H	Chief Executive Officer	May 08 '24	Buy	2.04	12,255	25,000	12,425	May 10 07:30 AM
Petersen Greg	Director	May 08 '24	Buy	2.04	12,255	25,000	36,421	May 10 07:30 AM
Clowes Howard	Director	May 08 '24	Buy	2.04	9,804	20,000	21,497	May 10 07:30 AM
Hawkins Richard J	Director	May 08 '24	Buy	2.04	4,902	10,000	4,903	May 10 07:30 AM
Lenk Robert P	Director	May 08 '24	Buy	2.04	4,167	8,501	29,327	May 10 07:30 AM
HEDRICK MARC H	Chief Executive Officer	Nov 20 '23	Sale	1.96	2,068	4,053	170	Dec 15 05:09 PM
Lenk Robert P	Director	Nov 16 '23	Buy	1.95	1,000	1,950	25,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 15 '23	Buy	1.77	1,000	1,770	24,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 13 '23	Buy	1.43	4,000	5,720	23,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 10 '23	Buy	1.45	2,000	2,900	19,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 08 '23	Buy	1.65	5,000	8,250	12,961	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 09 '23	Buy	1.59	4,199	6,676	17,160	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 07 '23	Buy	1.64	6,000	9,840	7,961	Nov 08 07:00 AM
Lenk Robert P	Director	Nov 06 '23	Buy	1.50	1,395	2,092	1,961	Nov 08 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTV

Plus Therapeutics Inc

Upgrade your FINVIZ experience